Philadelphia University + Thomas Jefferson University

Highlights

Andrea Barsevick, PhD 

Andrea Barsevick published "Advancing Symptom Science Through Symptom Cluster Research: Expert Panel Proceedings and Recommendations". Christine Miaskowski, Andrea Barsevick, Ann Berger, Rocco Casagrande, Patricia A. Grady, Paul Jacobsen, Jean Kutner, Donald Patrick, Lani Zimmerman, Canhua Xiao, Martha MatochaSue MardenJournal of the National Cancer Institute, 2017, April. DOI: https://doi.org/10.1093/jnci/djw253

Charnita Zeigler-Johnson, PhD, MPH

Presented -- “Characteristics of Local Geographic Areas with Low and High Prostate Cancer Risk” (accepted at NAACCR, oral presentation June 2017)

Presenting -- “Uncovering African American Males’ Understanding and Perceptions about Prostate Cancer Screening: Formative Research for a Neighborhood-Based Educational Intervention” (accepted at 2017 CDC National Cancer Conference, poster presentation August 2017)

Dream Team Member, The Pennsylvania Prostate Cancer Coalition

Talk – “Cancer Research and Advocacy -- A Researcher’s Perspective”, American Association for Cancer Research Representative, Sista Strut, Philadelphia, PA (June 2017)

Presentation -- “Characteristics of Local Geographic Areas with Low and High Prostate Cancer Risk” (accepted at NAACCR, oral presentation June 2017)

Membership -- Stakeholder Leadership Team, Pennsylvania Department of Health

ASPO 2018 Program Committee Member

Presented “Characteristics of Local Geographic Areas with Low and High Prostate Cancer Risk” (accepted at NAACCR, oral presentation, Albuquerque, New Mexico, June 2017).

Panelist at the Global Health Career Pathways, Center for Global Health, University of Pennsylvania, Philadelphia, PA,  March 25, 2017.

Presented “A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness.”  (Published in  PLoS One).

Hee-Soon Juon, PhD

Obieta K*, Juon HS. Racial and gender differences in prevalence of smoking and secondhand smoke and related factors from the 2009 CHIS. Poster presentation at Society of Behavior Medicine (SBM) meeting (3/29-4/1/2017), San Diego, CA.

Lhamo T*, Juon HS. Racial differences in prevalence of diabetes and diabetes self-management using CHIS. Poster presentation at SBM meeting (3/29-4/1/2017), San Diego, CA.

Guo J*, Juon HS, Lee S. Colorectal cancer knowledge and screening among Asian Americans aged 50-75 years old. Poster presentation at AACR meeting, Washington DC (4/1 – 4/5/2017) Note. *student 

Amy Leader, DrPH, MPH

Amy Leader is a winner of the second Accelerate Clinical Trials (ACT) Research Grant Award from Free to Breathe, an organization develoted to improving the treatment and survival of lung cancer patients. The ACT grant is a funding opportunity launched by Free to Breathe to investigate strategies to increase patient enrollment in therapeutic lung cancer clinical trials.  The intent of this grant program is to fund projects that will be reproducible and implementable within clinical practice.  An overall goal is to improve rates of patient accrual to lung cancer clinical trials by at least 50% within a defined healthcare facility, system, or community (April 2017).

Ronald Myers, PhD

Ronald Myers is one of the top 16 ASPO abstracts for 2017 to be published in Cancer Epidemiology, Biomarkers & Prevention Decision Support and Navigation to Increase Colorectal Cancer Screening among Hispanic Primary Care Patients Myers RE, Stello B, Daskalakis C, Sifri R, DiCarlo M, Johnson M, Gonzalez E, Hegarty S, Rivera A, Gordis-Molina L, Shaak K, Quinn A, Careyva B, Anderson-Ortiz R. The study compared the impact of a novel decision support and navigation intervention (DSNI) to a mailed standard intervention (SI) on colorectal cancer (CRC) screening among Hispanic patients from 5 primary care practices in the Lehigh Valley Health Network (LVHN). Methods. We randomized surveyed and consented patients who were 50 to 75 years of age and were eligible for CRC screening either to an SI Group (n=200) or a DSNI Group (n=200). Following randomization, SI Group participants were mailed a set of standard materials (i.e., a letter from the participant’s primary care practice encouraging selection and performance of either colonoscopy screening or a stool blood test (SBT) screening, a SBT kit, and instructions for arranging a colonoscopy appointment. Print materials were provided in English and Spanish. DSNI Group participants were also mailed the standard materials. In addition, DSNI participants received a telephone call from a bilingual patient navigator who reviewed the screening materials and verified the participant’s preferred CRC screening test. During the call, the patient navigator used an online Decision Counseling Program© (DCP) to determine the participant’s likelihood of test performance and to develop a personalized test preference- and likelihood-based screening plan. The plan was mailed to the participant and his/her primary care practice; and a participant screening status report was sent to the practice at 6 months. Finally, a 6-month survey was targeted to participants in both study groups. Results. Based on 6-month survey and medical records data, we found that CRC screening adherence was significantly higher (OR=3.48, CI: 2.29, 5.29, p<0.001) in the DSNI Group (73%) versus the SI Group (44%). Conclusions. A decision support and navigation intervention significantly increased CRC screening adherence among Hispanic primary care patients.

Veda Giri, MD

Boston, MA (UroToday.com) Dr. Veda Giri provided a high-level talk educating the audience regarding the latest consensus statement on genetic testing for prostate cancer risk at this afternoon’s Society of Urologic Oncology 2017 AUA Annual meeting.

Dr. Giri elegantly delineated why we need a consensus statement in 2017, noting the recent studies linking BRCA2 mutation to aggressive prostate cancer, higher rates of prostate cancer in families with Lynch syndrome, and the GWAS study identifying multiple common variants in PSA risk. Prostate cancer multigene panels have certainly focused on BRCA1/2 mutations, and Dr. Giri notes that this these specific mutations are now mentioned in the most recent NCCN guidelines. But the questions remain, how do we manage, screen and test these patients? Dr. Giri outlined that the framework of the consensus statement for genetic evaluation of inherited prostate cancer is broken down to referral criteria, genetic counseling, genetic testing, and management.

The criteria for referral for genetic counselling (with excellent consensus agreement) included patients that either have (i) first degree relatives diagnosed with prostate cancer ≤55 years of age or personal diagnosis of prostate cancer diagnosis ≤55 years of age with first degree relative diagnosed with prostate cancer at any age or death from prostate cancer in first degree relative at age ≤60 years of age; or (ii) two close blood relatives with prostate cancer on the same side of the family with at least one diagnosed ≤55 years of age; or (iii) any first degree relative with cancer in hereditary (ie. Lynch) syndrome, diagnosed with prostate cancer ≤50 years of age; or (iv) tumor sequencing showing mutations in hereditary cancer genes.

The criteria that should be considered for genetic testing for inherited prostate cancer (moderated to excellent consensus agreement) include patients with prostate cancer that have (i) families with syndromes consistent with hereditary breast, ovarian or prostate cancer or Lynch syndrome; or (ii) men with ≥2 close blood relatives on the same familial side; or (iii) all men with metastatic CRPC (67% consensus agreement). Recommendations specific to which genes should be tested included expanding genetic testing to include hereditary cancer syndromes (ie BRCA1/2, HOXB13) or broader family cancer history, and to provide context of relevance of genes based upon family history of disease aggressiveness.

For patients that have mutations, the panel developed consensus statements as to how to screen these patients. For men with BRCA2 mutation, consensus was 56% for obtaining a PSA at age 40 or 10 years prior to youngest prostate cancer diagnosed in the family. Furthermore, the interval of screening should be yearly or determined by baseline PSA (76% consensus). For patients with HOXB13 mutation, similar recommendations are made as to men with BRCA2 mutation – this is the first such recommendations for patients with HOXB13 mutation.

In summary, this is the first centralized, multi-disciplinary consensus to address a working framework for addressing genetic evaluation for inherited prostate cancer. As Dr. Giri concludes “this is a dynamic field that will require updating of the guidelines in the future.”

Presenter: Veda Giri, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre
Twitter: @zklaassen_md

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA